» Articles » PMID: 26732691

Regression Approaches in the Test-negative Study Design for Assessment of Influenza Vaccine Effectiveness

Overview
Date 2016 Jan 7
PMID 26732691
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Influenza vaccination is the most practical means available for preventing influenza virus infection and is widely used in many countries. Because vaccine components and circulating strains frequently change, it is important to continually monitor vaccine effectiveness (VE). The test-negative design is frequently used to estimate VE. In this design, patients meeting the same clinical case definition are recruited and tested for influenza; those who test positive are the cases and those who test negative form the comparison group. When determining VE in these studies, the typical approach has been to use logistic regression, adjusting for potential confounders. Because vaccine coverage and influenza incidence change throughout the season, time is included among these confounders. While most studies use unconditional logistic regression, adjusting for time, an alternative approach is to use conditional logistic regression, matching on time. Here, we used simulation data to examine the potential for both regression approaches to permit accurate and robust estimates of VE. In situations where vaccine coverage changed during the influenza season, the conditional model and unconditional models adjusting for categorical week and using a spline function for week provided more accurate estimates. We illustrated the two approaches on data from a test-negative study of influenza VE against hospitalization in children in Hong Kong which resulted in the conditional logistic regression model providing the best fit to the data.

Citing Articles

Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness.

Li K, Shi X, Miao W, Tchetgen Tchetgen E J Am Stat Assoc. 2024; 119(547):1859-1870.

PMID: 39524693 PMC: 11545655. DOI: 10.1080/01621459.2023.2220935.


Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.

Guo Z, Zeng T, Lu Y, Sun S, Liang X, Ran J Commun Med (Lond). 2024; 4(1):92.

PMID: 38762678 PMC: 11102477. DOI: 10.1038/s43856-024-00521-y.


Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.

He X, Liao Y, Liang Y, Yu J, Gao W, Wan J Front Immunol. 2024; 14:1290279.

PMID: 38259438 PMC: 10800792. DOI: 10.3389/fimmu.2023.1290279.


Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.

Zeng T, Lu Y, Zhao Y, Guo Z, Sun S, Teng Z Respir Res. 2023; 24(1):246.

PMID: 37828565 PMC: 10571409. DOI: 10.1186/s12931-023-02542-y.


Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China.

Zeng T, Wang K, Guo Z, Sun S, Zhai Z, Lu Y Infect Dis Ther. 2023; 12(10):2405-2416.

PMID: 37768483 PMC: 10600082. DOI: 10.1007/s40121-023-00873-3.


References
1.
Koul P, Broor S, Saha S, Barnes J, Smith C, Shaw M . Differences in influenza seasonality by latitude, northern India. Emerg Infect Dis. 2014; 20(10):1723-6. PMC: 4193176. DOI: 10.3201/eid2010.140431. View

2.
Mansournia M, Hernan M, Greenland S . Matched designs and causal diagrams. Int J Epidemiol. 2013; 42(3):860-9. PMC: 3733703. DOI: 10.1093/ije/dyt083. View

3.
Jackson M, Nelson J . The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013; 31(17):2165-8. DOI: 10.1016/j.vaccine.2013.02.053. View

4.
Osterholm M, Kelley N, Sommer A, Belongia E . Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2011; 12(1):36-44. DOI: 10.1016/S1473-3099(11)70295-X. View

5.
Jackson L, Jackson M, Nelson J, Neuzil K, Weiss N . Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2005; 35(2):337-44. DOI: 10.1093/ije/dyi274. View